The expression of inhibitor of bruton’s tyrosine kinase gene is progressively up regulated in the clinical course of chronic lymphocytic leukaemia conferring resistance to apoptosis

Chronic lymphocytic leukaemia (CLL) is the most common B-cell malignancy with a variable clinical outcome. Biomarkers of CLL progression are required for optimising prognosis and therapy. The Inhibitor of Bruton’s tyrosine kinase—isoform α (IBTKα) gene encodes a substrate receptor of Cullin 3-depend...

Descripción completa

Detalles Bibliográficos
Autores principales: Albano, Francesco, Chiurazzi, Federico, Mimmi, Selena, Vecchio, Eleonora, Pastore, Arianna, Cimmino, Clementina, Frieri, Camilla, Iaccino, Enrico, Pisano, Antonio, Golino, Gaetanina, Fiume, Giuseppe, Mallardo, Massimo, Scala, Giuseppe, Quinto, Ileana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5849039/
https://www.ncbi.nlm.nih.gov/pubmed/29317636
http://dx.doi.org/10.1038/s41419-017-0026-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5849039/
https://www.ncbi.nlm.nih.gov/pubmed/29317636
http://dx.doi.org/10.1038/s41419-017-0026-3

Ejemplares similares